Molecular-based techniques reduce the delay in diagnosing infectious diseases and therefore contribute to better patient outcomes. We assessed the FilmArray blood culture identification (BCID) panel (Biofire Diagnostics/bioMé rieux) directly on clinical specimens other than blood: cerebrospinal, joint, pleural and ascitic fluids, bronchoscopy samples and abscesses. We compared the results from 88 samples obtained by culture-based techniques. The percentage of agreement between the two methods was 75 % with a Cohen k value of 0.51. Global sensitivity and specificity using the FilmArray BCID panel were 71 and 97 %, respectively. Sensitivity was poorer in samples with a low bacterial load, such as ascitic and pleural fluids (25 %), whereas the sensitivity for abscess samples was high (89 %). These findings suggest that the FilmArray BCID panel could be useful to perform microbiological diagnosis directly from samples other than positive blood cultures, as it offers acceptable sensitivity and moderate agreement with conventional microbiological methods. Nevertheless, cost-benefit studies should be performed before introducing this method into algorithms for microbiological diagnostics.
INTRODUCTION
Time is crucial when managing infectious diseases. Conventional culture-based methods are slow to give definitive results. Rapid culture-independent methods contribute to a better initial management of patients and more efficient use of antimicrobials (Picard & Bergeron, 2002; Bissonnette & Bergeron, 2006; Pozzetto et al., 2010) . Culture-independent methods such as nucleic acid amplification tests are being increasingly used for diagnosis of infectious diseases. The FilmArray platform is one of the few commercially available systems using nucleic acid amplification tests to diagnose infectious diseases (Poritz et al., 2011) . Briefly, it is a nested multiplex PCR system that performs all the assay steps, from nucleic acid extraction to interpretation of amplification data, in a closed system using a single panel on a minimally processed clinical sample in a completely automated manner. Most importantly, it gives results in just 1 h. Additionally, the laboratory procedures are not technologically complex and no special training is required. Accordingly, this technology has the potential to significantly improve the management of several infectious diseases.
Three FilmArray panels are commercially available, a respiratory panel, a gastrointestinal panel and a blood culture identification (BCID) panel (Poritz et al., 2011; Blaschke et al., 2012; Khare et al., 2014) . The FilmArray BCID panel was designed to detect 24 pathogens associated with bloodstream infections, and three antimicrobial resistance genes (vanA/B, mecA and bla KPC ) ( Table 1) . These pathogens included in the FilmArray BCID panel cause many other infectious processes (Almuhayawi et al., 2014; Bhatti et al., 2014) . Accordingly, we hypothesized that off-label use of the FilmArray BCID panel directly on clinical specimens other than blood could improve the management of other severe infections, such as meningitis or pneumonia. In this study, we assessed the applicability of the FilmArray BCID panel to diagnose infectious diseases other than sepsis directly from samples in a totally cultureindependent manner.
METHODS
This study was performed in the microbiology laboratory of the Hospital de la Santa Creu i Sant Pau, a tertiary hospital in Barcelona, Spain. The Research Institute of Hospital de la Santa Creu i Sant Pau and the Clinical Ethics Committee approved this study (IIBSP-FIL-2013-57; 18/2013) . Informed consent was waived because the study was prospective without interaction with patients and all patient personal information was de-identified prior to analysis.
The flow chart in Fig. 1 illustrates sample selection and processing criteria. Only those samples with a higher probability of a positive outcome were included: (i) fluids from normally sterile sites [cerebrospinal (CSF), joint, ascitic and pleural fluids] with microorganisms or polymorphonuclear cells observed on a Gram stain; (ii) lower respiratory tract samples obtained by bronchoscopy [protected specimen brush (PSB) and bronchoalveolar lavage fluid (BAL)] from immunocompetent patients; and (iii) abscess samples with microorganisms on a Gram stain. Samples processed for this study were collected prospectively at our laboratory on working days from 8 a.m. to 8 p.m. from April to October 2013. As samples were processed immediately after arrival at our laboratory, no storage was needed.
After Gram staining, all samples selected for this study were processed using the FilmArray BCID panel, as well as conventional culturebased methods, at the same time. Results obtained by the FilmArray BCID panel were blinded. For the FilmArray BCID panel, we followed the manufacturer's indications as recommended for blood cultures, using 100 ml of well-mixed samples directly without previous centrifugation and with no special adaptation to the samples. The FilmArray BCID panel contains all the required reagents for sample preparation, reverse transcription-PCR, PCR and detection in a freeze-dried, room-temperature stable format. The samples and hydration solution are injected into the pouch prior to the run. The panel is then introduced into the device and results are obtained in 1 h.
For the conventional culture-based laboratory methods, we performed our standard procedures: Gram staining, culture and identification of isolates. All micro-organisms isolated by culture-based methods were identified with Vitek 2 identification cards (bioMér-ieux) with the exception of anaerobes, which were identified with RapID ANA II System identification panels (Remel, Thermo Scientific). Micro-organisms with no consistent results using conventional methods were identified by 16S rRNA gene sequencing . Antimicrobial susceptibility testing was performed according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI, 2012) . The turnaround time for standard methods is 24-48 h. All strains isolated in cultures were stored for further analyses. We performed the FilmArray panel with those strains isolated from samples that were FilmArray negative/culture positive to confirm the functionality of the molecular design of the FilmArray.
To confirm the clinical significance of the results, we collected clinical data (pre-existing pathology, demographic data, clinical outcome, and empirical and directed treatment) from the clinical records and evaluated the results from other samples if available (blood cultures, antigen detection and other cultures). This additional information was useful to decide the clinical relevance of the culture and FilmArray panel results. We considered a positive result to be clinically significant when the microbiological results from the FilmArray panel or the culture-based methods, or both, were concordant with clinical data (Isenberg, 2004 
RESULTS
During the 6 months of the study, a total of 88 samples were processed using both the FilmArray BCID panel and conventional culture-based methods. These samples were 41 fluids from normally sterile sites (19 CSF, eight pleural fluids, seven ascitic fluids and seven joint fluids), 36 lower respiratory tract samples (15 bronchoalveolar lavage fluids and 21 protected specimen brushes) and 11 abscess samples.
Global results for the FilmArray BCID panel and culture-based methods
From the total of 88 samples, 57 (65 %) specimens were positive (Table 2) 
Detection of organisms and antibiotic resistance markers
We isolated 86 different micro-organisms from the 51 samples that were positive using standard culture methods (Table 3) . Sixteen of these 51 samples were positive for more than one micro-organism. Seven of these 16 samples were from abscesses, six were from respiratory samples (four PSB and two BAL), two were from ascitic fluid and one was from pleural fluid. Seventy-two of the 86 (84 %) were pathogens included in the FilmArray BCID panel. The 14 micro-organisms not included in the panel were four Bacteroides spp., three Fusobacterium spp., three JF, joint fluid; AF, ascitic fluid; PF, pleural fluid; AS, abscess samples. *The FilmArray panel was negative, even using probes for Enterobacteriaceae. DFour Bacteroides sp., three Fusobacterium sp., three Propionibacterium acnes, one Clostridium perfringens, one Burkholderia gladioli, one Bordetella bronchiseptica and one Stenotrophomonas maltophilia. 'Dominant' means that most of the corresponding samples positive for a given micro-organism give the stated result for culture and FilmArray.
Propionibacterium acnes, one Clostridium perfringens, one Burkholderia gladioli, one Bordetella bronchiseptica and one Stenotrophomonas maltophilia. The FilmArray panel detected 57 (79 %) of the 72 micro-organisms isolated by culture and included in the FilmArray BCID panel. Eighteen of the 51 samples were polymicrobial using the FilmArray panel: six samples were from abscesses, 11 were from respiratory samples (seven PSB and four BAL) and one was from ascitic fluid.
We did not detect any meticillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci strains or bla KPCcarrying strains. There were no pouch failures.
Results according to clinical assessment
Fifty-six of the 88 (64 %) specimens were considered true infections (Table 4) .
For the FilmArray BCID panel-positive discrepant results, of the 56 samples considered true infections, five were culture negative/FilmArray BCID panel positive. Three of these were Streptococcus pneumoniae (two from CSF and one from PSB), one was coagulase-negative Staphylococcus from CSF from a ventriculoperitoneal (VP) shunt, and one was Candida glabrata from PSB (Table 3 ). The two Streptococcus pneumoniae from CSF were also detected by immunochromatography in CSF (BinaxNow; Alere). One of the two Streptococcus pneumoniae isolates from CSF and the S. pneumoniae isolate from PSB were also isolated from blood cultures. The coagulase-negative Staphylococcus was also isolated from the VP shunt catheter tip culture.
Finally, Candida glabrata was also isolated from blood culture.
For the culture-positive discrepant results, of the 56 samples considered true infections, 16 were culture positive/ FilmArray BCID panel negative. These corresponded to three ascitic fluids (one Escherichia coli, two viridans group streptococci and one Clostridium perfringens), three pleural fluids (culture positive for one viridans group streptococci and one Enterobacter cloacae complex, while one was polymicrobial with Corynebacterium spp., Bacteroides spp. and Fusobacterium spp.), three BAL (one Burkholderia gladioli, one Bordetella bronchiseptica and one Stenotrophomonas maltophilia), three joint fluids (Serratia marcescens, viridans group streptococci and Morganella morganii), three CSF (VP shunt; two Propionibacterium acnes and one Pseudomonas aeruginosa) and one abscess sample with one Staphylococcus epidermidis (Table 3) . One viridans group Streptococcus from an ascitic fluid sample was also isolated from two blood cultures. Viridans group Streptococcus from pleural fluid was also isolated from a PSB from the same patient. The Serratia marcescens obtained from a joint fluid was also isolated from another joint fluid from the same patient. The Morganella morganii isolated from a joint fluid was also isolated from several surgical samples from the same patient. The Bordetella bronchiseptica was also isolated from several BALs from the same patient. The Pseudomonas aeruginosa isolated from a CSF was also isolated from the VP shunt catheter tip culture. Finally, one of the two Propionibacterium acnes obtained from CSF was also isolated from other CSFs obtained from the same patient. Table 5 summarizes the results for each specimen. The global sensitivity and specificity of the culture were 91 % (95 % CI 80-97 %) and 100 % (95 % CI 87-100 %), respectively, whereas for the FilmArray BCID panel they were 71 % (95 % CI 58-82 %) and 97 % (95 % CI 82-100 %), respectively.
The sensitivity of the FilmArray BCID panel was lower for sterile fluids (between 25 % for ascitic and pleural fluids and 73 % for CSF) than for culture-based methods.
In the respiratory samples, sensitivity ranged from 70 % for BAL to 100 % for PSB. Sensitivity was 89 % for purulent samples. The specificity of the FilmArray BCID panel ranged from 80 to 100 %.
DISCUSSION
Our findings indicate that the FilmArray BCID panel could be useful for the diagnosis of several infectious processes besides those in the blood stream. Nevertheless, in view of the cost of the platform, a strict algorithm would be required to select samples in order to maximize profitability and decrease general costs. The percentage of agreement between the molecular approach with the FilmArray BCID panel and conventional culture methods was 75 %, with a Cohen k value of 0.51, indicating a moderate agreement. (Isenberg, 2004) . DCulture results: sensitivity 91 % (95 % CI 80-97 %), specificity 100 % (95 % CI 87-100 %), positive predictive value 100 % (95 % CI 91-100 %), negative predictive value 86 % (95 % CI 70-95 %). dFilmArray BCID panel results: sensitivity 73 % (95 % CI 59-84 %), specificity 97 % (95 % CI 82-100 %), positive predictive value 98 % (95 % CI 86-100 %), negative predictive value 67 % (95 % CI 52-80 %). The only specimen with a non-TI-positive FilmArray result was considered a contaminated specimen.
FilmArray BCID efficacy in samples other than blood
A similar Cohen k value is frequently observed with new molecular approaches (Carrara et al., 2013) . There are several possible explanations: first, not all micro-organisms are included in the panel of micro-organisms detected by the molecular approach; second, viable micro-organisms are studied using the conventional culture approach but molecular approaches are used for DNA; and third, the sample volume processed for each method differs Ginocchio & McAdam 2011; Carrara et al., 2013) .
Another crucial point in validating new molecular approaches is the selection of the 'gold standard'. When we took the culture results as the gold standard, we obtained a global analytical sensitivity for the FilmArray BCID panel of 78 %. When we took molecular and culture results into consideration together with other analytical and clinical results to obtain the gold standard, the global sensitivity and specificity of the culture were 91 % (95 % CI 80-97 %) and 100 % (95 % CI: 87-100 %), respectively, whereas for the FilmArray BCID panel they were 71 % (95 % CI 58-82 %) and 97 % (95 % CI 82-100 %), respectively. These values are in concordance with many other molecular approaches and emphasize, once again, that the accuracy of a specific molecular approach differs depending on the sample, the micro-organisms involved, the expected bacterial load and the presence of nucleic acids from non-pathogenic bacteria (commensal microbiota) Soriano et al., 2011) . On the other hand, the sensitivity and specificity were lower than those obtained when the FilmArray BCID panel was used in positive blood cultures (Poritz et al., 2011; Altun et al., 2013) .
We should emphasize that the FilmArray BCID panel has been approved and commercialized for positive blood cultures only. Accordingly, there are no data regarding its use with samples other than blood cultures. The sensitivity of the FilmArray BCID panel for sterile fluids was poor in our study, ranging from 25 % in ascitic and pleural fluids to 73 % in CSF. These FilmArray BCID false-negative results corresponded to three ascitic and three pleural fluids. Two of the ascitic fluids were positive only from blood culture bottles (where 5 ml of sample was inoculated). The remaining ascitic fluid was positive for less than 200 c.f.u. ml 21 on a blood agar plate. Two of the pleural fluid samples were positive for about 2000 c.f.u. ml 21 . Finally, the remaining pleural fluid sample was positive for micro-organisms not included in the FilmArray BCID panel. We consider that these low percentages were due to the characteristic low colony count in most ascitic and pleural fluid infections (Tassi et al., 2010; Lippi et al., 2014) . The use of a larger sample would probably increase the sensitivity in this kind of sample. Another possible explanation for the discrepant FilmArray BCID panel-negative/culture-positive results could be the low sensitivity of primers and probes. Nevertheless, we ruled this possibility out by performing the assay directly from the growing isolates, instead of from the specimen. In all cases, the FilmArray BCID panel was positive when performed from the isolate. Finally, we should take into consideration the possibility of micro-organisms not included in the panel.
We hypothesize that the low sensitivity of the test could be related to the volume of sample used and the bacterial load, as mentioned above (Carrara et al., 2013) . The FilmArray BCID panel sensitivity for abscess samples was high (89 %). To the best of our knowledge, there are no data in the literature about using molecular techniques for such samples. In all the aforementioned cases, the specificity was 100 %. The respiratory samples differed considerably from the other samples evaluated (sterile fluids and abscesses): the sensitivity ranged from 70 % for BAL to 100 % for PSB, whereas the specificity ranged from 80 % for BAL to 100 % for PSB. Among the 36 LRT samples, the FilmArray BCID panel detected 10 micro-organisms that were not detected by culture. An important point that could be controversial is that seven of these respiratory samples were considered as possibly being contaminated by DNA from oral flora [Haemophilus influenzae (n55) and S. pneumoniae (n52)]. Accordingly, the FilmArray BCID panel seems to be more sensitive than culture. However, it should be pointed out that most molecular approaches can detect DNA from micro-organisms other than those involved in the infectious process, which could complicate the clinical interpretation of results. The detection of DNA from micro-organisms not involved in the infectious process, or at least from those not able to grow in conventional culture, has already been observed in other clinical situations, such as in the diagnosis of peritonitis and particularly in viral respiratory infections in children (Ginocchio & McAdam, 2011) . Finally, we should mention that the low negative predictive value of the FilmArray BCID panel (67 %) was mainly due to the relatively high number of samples with micro-organisms not included in the panel. Most of these micro-organisms are anaerobes or non-fermenting Gram-negative bacilli.
Detection of resistance genes is a valuable advantage of these new molecular technologies, but in the present study, we did not detect any of the resistance genes tested (van, mecA or bla KPC ). This is in concordance with the prevalence of these antimicrobial resistance genes in our environment (http:// www.santpau.es/santpau/activitats/inicioMicrobiologia.htm). Accordingly, the possible addition of other resistance markers within the panel, consistent with the resistance prevalence, should be taken into consideration. The absence of van, mecA or bla KPC antimicrobial resistance genes in our environment is an important limitation of this study in evaluating the accuracy of the FilmArray BCID panel in detecting these resistance genes.
In conclusion, this study assessed the applicability and viability of the multiplex PCR-based FilmArray BCID panel. This panel could be recommended as a routine diagnostic method for direct use on samples other than positive blood cultures as it offers acceptable sensitivity and moderate agreement with conventional microbiological methods. Indeed, the manufacturer, Biofire, is currently developing a new meningitis/encephalitis panel to detect most of the viruses and bacteria involved in these pathologies. Costbenefit studies will be needed, however, before it can be introduced into algorithms for microbiological diagnosis.
